ストックスクリーナーアプリを入手
46.46
0.69%
0.32
前日終値:
$46.14
開ける：
$45.83
24時間の取引高:
834.75K
Relative Volume:
0.55
時価総額：
$6.08B
収益：
-
当期純損益:
$-507.65M
株価収益率:
-10.10
EPS:
-4.6
ネットキャッシュフロー:
$-616.24M
1週間 パフォーマンス:
-1.09%
1か月 パフォーマンス:
+3.94%
6か月 パフォーマンス:
+39.65%
1年 パフォーマンス:
-44.23%
1日の値動き範囲:
$45.83
$47.76
1週間の範囲:
$45.21
$47.76
52週間の値動き範囲:
$27.66
$93.77
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
46.46 | 6.04B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-12 | 開始されました | Goldman | Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Insider Sell Alert: Harpreet Dhaliwal Sells 9,743 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Harpreet Dhaliwal Sells 9,743 Shares of Vaxcyte (NASDAQ:PCVX) Stock - MarketBeat
Price-Driven Insight from (PCVX) for Rule-Based Strategy - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Nasdaq Composite Tracks Clinical Progress - Kalkine Media
Trade Alert: Senior Vice President of Finance Of Vaxcyte Elvia Cowan Has Sold Stock - simplywall.st
Vaxcyte (NASDAQ:PCVX) Stock Price Up 3.9%Here's Why - MarketBeat
Vaxcyte shows rising price performance with jump to 81 RS rating - MSN
Insider Selling: Vaxcyte (NASDAQ:PCVX) SVP Sells 11,623 Shares of Stock - MarketBeat
Vaxcyte president and CFO sells shares worth $692,100 - MSN
Vaxcyte, Inc. $PCVX Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
Vaxcyte Earnings Notes - Trefis
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. - Barron's
What Makes Vaxcyte (PCVX) So Attractive - Finviz
What makes Vaxcyte (PCVX) so attractive - MSN
How (PCVX) Movements Inform Risk Allocation Models - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Vaxcyte Inc. stock remains resilientJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - Улправда
Assenagon Asset Management S.A. Buys 171,974 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Will Vaxcyte Inc. stock keep outperforming rivalsM&A Rumor & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Vaxcyte Inc. stock performs during Fed tightening cyclesDay Trade & Safe Capital Allocation Plans - Улправда
How Vaxcyte Inc. stock performs in rate cut cyclesAnalyst Downgrade & Safe Capital Growth Trade Ideas - Улправда
Vaxcyte Enhances Executive Severance to Align With Market - TipRanks
PCVX (Vaxcyte) EV-to-OCF : -7.70 (As of Dec. 19, 2025) - GuruFocus
Profit Review: Will Vaxcyte Inc. stock attract ESG investorsWeekly Risk Summary & Reliable Intraday Trade Plans - DonanımHaber
Why Vaxcyte Inc. (5VA) stock remains stableTrade Entry Report & AI Powered Trade Plan Recommendations - Улправда
Vaxcyte enhances executive severance to align with market - MSN
Vaxcyte: Financial Durability And The Case For Disruption (NASDAQ:PCVX) - Seeking Alpha
Market Review: Why Vaxcyte Inc stock could benefit from AI revolution2025 Geopolitical Influence & Fast Moving Stock Watchlists - moha.gov.vn
Pivotal OPUS Phase 3 VAX-31 Head-to-Head Trial Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
How Vaxcyte’s Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors - Yahoo Finance
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price - Yahoo Finance
Frazier Life Sciences Management L.P. Reduces Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Institutional Investors Bet Big on Vaxcyte’s Clinical Ambitions - AD HOC NEWS
Vaxcyte, Inc. $PCVX Shares Purchased by Eventide Asset Management LLC - MarketBeat
Vaxcyte, Inc. $PCVX Shares Purchased by Maverick Capital Ltd. - MarketBeat
Vaxcyte, Inc. (PCVX) makes strides on pneumonia treatment, plots coverage extension - MSN
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension - Yahoo Finance
Trading Systems Reacting to (PCVX) Volatility - Stock Traders Daily
Vaxcyte, Inc. $PCVX Stake Increased by Diadema Partners LP - MarketBeat
Vaxcyte (PCVX) Gets a Buy from Guggenheim - The Globe and Mail
Vaxcyte (PCVX) price target increased by 19.72% to 99.96 - MSN
Vaxcyte stock maintains Buy rating at Jefferies as Phase 3 trial begins - Investing.com Canada
Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia - marketscreener.com
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31 - TipRanks
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 - Investing.com
Vaxcyte (PCVX) Begins Phase 3 Study for Pneumonia Vaccine - GuruFocus
Vaxcyte says topline results from OPUS trial expected in Q4 2026 - marketscreener.com
Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026 - TradingView
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 By Investing.com - Investing.com Canada
Vaxcyte Finalizes Trial Design for VAX-31, Aiming to Set New Standard for Adult Pneumococcal Vaccines in Consultation with FDA - Quiver Quantitative
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):